Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hoogkamp-Korstanje, J. A.
Right arrow Articles by Davies, B. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hoogkamp-Korstanje, J. A.
Right arrow Articles by Davies, B. I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy, Vol 39, 411-414, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy

JOURNAL ARTICLE

Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin

JA Hoogkamp-Korstanje, SI Dirks-Go, P Kabel, WL Manson, EE Stobberingh, RW Vreede and BI Davies
Department of Medical Microbiology of University Hospital St Radboud, Nijmegen, The Netherlands.

Seven laboratories, including a reference laboratory, tested the susceptibility of Moraxella catarrhalis, Streptococcus pneumoniae and Haemophilus influenzae strains to ciprofloxacin, clarithromycin, co- amoxiclav and sparfloxacin with the Etest. A total of 976 strains were collected. The results with ciprofloxacin and sparfloxacin were consistent for all laboratories, while those with clarithromycin and co- amoxiclav were not. The agreement between Etest MICs and broth microdilution was: ciprofloxacin and sparfloxacin, >95%; clarithromycin for all species, 71-85%; co-amoxiclav for H. influenzae, 31%. MIC90 values (broth dilution, mg/L) for M. catarrhalis, S. pneumoniae and H. influenzae were: sparfloxacin, 0.06, 0.5, 0.03; ciprofloxacin, 0.12, 2.0, 0.03; co-amoxiclav, 0.25, 0.25, 0.25; clarithromycin 0.25, 0.25 and 16.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
C. M. Verduin, C. Hol, A. Fleer, H. van Dijk, and A. van Belkum
Moraxella catarrhalis: from Emerging to Established Pathogen
Clin. Microbiol. Rev., January 1, 2002; 15(1): 125 - 144.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
N. C. Weightman and M. Barnham
Effect of the incubation atmosphere on the susceptibilities of Haemophilus influenzae isolates to macrolides and amoxycillin as determined by the Etest
J. Antimicrob. Chemother., March 1, 2000; 45(3): 405 - 406.
[Full Text] [PDF]

Home page
 ThoraxHome page
P. J Moss and R. G Finch
The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults
Thorax, January 1, 2000; 55(1): 83 - 85.
[Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.